Robert I. Blum

Robert I. Blum is a declared insider at 2 companies (chief executive); the most frequent names are Cytokinetics Inc and Gamida Cell Ltd. We count 144 filings; the first trade dates from 7 May 2021 and the latest from 12 October 2026.

The open-market side counts 1 purchase for €79k alongside 43 sales for €21.8M. The amount is not disclosed for 2 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 15 share grants and 80 option exercises. Since January 2026: no purchases and 18 sales on the market.

The newest entry dates from 13 October 2026: an option exercise of €71k, in Cytokinetics Inc. The clock since the last published purchase (4 October 2022) now reads 1,475 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.